Type 2 diabetes. Type 2 diabetes mellitus
Conditions
Interventions
Intervention 1: Intervention Group 1: Participants in intervention group 1 will take tablets containing 250 mg of a combined distillation of Arctium lappa and jujube fruit syrup every 8 hours for thre
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to 70 Years
Inclusion criteria
Inclusion criteria: Suffering from Type II diabetes Use of oral hypoglycemic agents (individuals who manage their diabetes solely with blood sugar-lowering pills) Age over 40 years and less than or equal to 70years Body Mass Index (BMI) 18.5–30 kg/m² Fasting Blood Sugar =126 mg/dL Willingness to participate in the study
Exclusion criteria
Exclusion criteria: Suffering from Type I diabetes Other specific types of diabetes Insulin therapy in the past three months Presence of severe gastrointestinal (GI) diseases, including peptic ulcer and gastrointestinal bleeding History of diabetic ketoacidosis, hyperosmolar non-ketotic diabetic coma, severe infection, or surgery in the past month Uncontrolled hypertension (blood pressure =160/100 mmHg) Presence of mental illness or individuals with intellectual disabilities Pregnancy, breastfeeding, or planning to become pregnant Having cardiovascular diseases, kidney failure, liver dysfunction, thyroid or parathyroid disorders, and cancers Pregnancy, breastfeeding, or planning to become pregnant High physical activity Allergy to nettle Presence of chronic diabetic complications (neuropathy, retinopathy as per patients' medical records), diabetic nephropathy, hypothyroidism, and hyperthyroidism
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measurement of HbA1C levels. Timepoint: At the baseline (before intervention) and just after completion of the intervention (3 months after beginning the intervention ). Method of measurement: Fasting blood sample collection and HbA1C test.;Measurement of Fasting Blood Sugar (FBS). Timepoint: At the baseline (before intervention) and just after completion of the intervention (3 months after beginning the intervention ). Method of measurement: Fasting blood sample collection and FBS test.;Assessment of insulin resistance. Timepoint: At the baseline (before intervention) and just after completion of the intervention (3 months after beginning the intervention ). Method of measurement: Fasting blood glucose measurement through blood sampling and determination of insulin resistance using formula. | — |
Secondary
| Measure | Time frame |
|---|---|
| Determination of liver enzyme function (SGOT, SGPT, ALK). Timepoint: At the baseline (before intervention) and just after completion of the intervention (3 months after beginning the intervention ). Method of measurement: Fasting blood sample test.;Determination of serum markers of renal function (Urea, Cr). Timepoint: At the baseline (before intervention) and just after completion of the intervention (3 months after beginning the intervention ). Method of measurement: Fasting blood sample collection and testing for urea and creatinine.;Measurement of blood pressure. Timepoint: At the baseline (before intervention) and just after completion of the intervention (3 months after beginning the intervention ). Method of measurement: Measurement of systolic and diastolic blood pressure in a seated position.;Anthropometric measurements (weight, height, wrist circumference, waist circumference, arm circumference). Timepoint: At the baseline (before intervention) and just after completion of the intervention (3 months after beginning the intervention ). Method of measurement: Using a measuring tape and a stadiometer.;Determination of blood lipid parameters (HDL, LDL, TC, TG). Timepoint: At the baseline (before intervention) and just after completion of the intervention (3 months after beginning the intervention ). Method of measurement: Fasting blood sample. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAlireza Ostadrahimi
Tabriz University of Medical Sciences
Outcome results
None listed